



TSX Venture Exchange: CCG
FOR IMMEDIATE RELEASE

CardioComm Solutions Inc. Announces Q3, 2005 Financial Report **UPDATE ON CORPORATE DEVELOPMENTS**

VICTORIA, B.C., November 29, 2005– CardioComm Solutions Inc. (TSX-V:CCG) (the "Company", "CardioComm"), today announced its financial results for the third quarter ended September 30, 2005. Please refer to the Company's financial statements and management's discussion & analysis filed electronically at www.sedar.com.

Q3 Financials

Revenues for the third quarter of 2005 were \$191,495 compared to \$629,040 for the third quarter of 2004. This \$437,545 (71%) decrease in revenue over the same period 2004 is due primarily to a reduction in custom solutions co-development activity. CardioComm recorded a net loss of \$425,277 for the third quarter 2005 as compared to a net loss of \$143,627 in the same period last year.

General and Administrative expenditures were \$215,619 in the third quarter of 2005 as compared to \$306,379 in the same period last year. The expenses decreased by \$90,760 (30%). This substantial change was due to a decrease in stock compensation and regulatory expenses.

During the third quarter, Sales and Marketing expenditures were \$148,856 as compared to \$178,392 in the same period last year. The expenses decreased by \$29,536 (17%) for the third quarter of 2005 compared to the same period last year. The decrease in costs result from cost containment initiatives, and a decrease in various sales related expenses such as commissions.

Corporate Update

CardioComm is pleased to confirm that its corporate acquisition of CardioView Inc. and private placement are proceeding as previously announced. CardioComm and CardioView are concluding their respective due diligence and developing plans to jointly create a new 12 lead cardiac custom project for launch at the annual Heart Rhythm Society Conference in May, 2006. This moves the Company into Stage 3 of its long range plan which is to become a full web based ECG management system.

According to Frost & Sullivan 2005, U.S ECG and Cardiac Monitoring Products and Services Markets, the 2004 market size for product segment was \$295.7 million and the \$3.24 billion for the service side. The following key drivers in order of priority have been identified by Frost & Sullivan in order of their anticipated impact on ECG and Cardiac Monitoring Products for the forecast years 2005-2011:

1. Continued shift to networked facilities drives increased demand for integrated ECG data management systems

2. Advancements with PC-based systems drives market penetration of ECG instruments
3. Increased prevalence of cardiovascular disease drives continued utilization of diagnostic ECG tools
4. Physicians seeking new revenue streams ignite new sales opportunities in the primary care segment
5. Increased reimbursements in cardiac event monitoring fuel unit shipments

These drivers set up well for CardioComm as the marketing plans for GlobalCardio play off each driver bringing affordable, web based, consolidated ECG management to all sectors of the market. A technician or physician can now acquire all ECG related patient data from one system wherever there is an internet connection.

In addition to the 12 lead cardiac system, CardioComm continues to develop partner relationships using the HL7 interface engine. This is especially effective with certain distributors since common customers are seeing the benefit of this interface which will lead to an increased volume of larger sales over the next year. Lastly, CardioComm is working with new partners to enhance the sales package including a new interpretation algorithm which can be implemented for all ECG tests including event and resting 12 lead. The ECG Viewer Software Developers Kit is being evaluated by a number of companies to include in independent development efforts.

About CardioComm Solutions Inc:

CardioComm's patented and proprietary technology is used in products for the recording, viewing, analyzing and storing of electrocardiograms (ECGs), for diagnosis and management of cardiac patients. The Company's products are sold worldwide through a combination of its external distribution network and its North American based sales team. CardioComm has achieved its technical goals of improved access and communication through the development of a real-time ECG viewer. CardioComm is the first company to provide a real-time means of viewing ECGs over a network (LAN, WAN or Internet). This tool enables ECGs to be viewed and controlled live, by physicians, over a global virtual healthcare network. This technology is marketed as Global ECG Management System (GEMS™) and GlobalCardio™. CardioComm's software products have been cleared for sale in the United States by the U.S. Food and Drug Administration. The Company has earned the latest ISO 13485 certification.

On behalf of the Board of Directors
of CardioComm Solutions Inc.:

“Stephen Martin”

Stephen R. Martin, President & CEO

For investor information, please

contact:

Derek Sutherland

IR@CardioComm.com

Call 1-416-832-0442

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the accuracy of this release.